Syzygium alternifolium
Syzygium alternifolium · Accepted scientific name
Scientific literature: Very Sparse (4 studies) · ★☆☆☆☆
Syzygium alternifolium is a significant botanical species recognized for its diverse range of therapeutic potential. Research into its medicinal properties has highlighted its noteworthy antihyperglycemic, antimicrobial, and gastroprotective activities. Studies focusing on various preparations, including aqueous extracts, ethanol, hexane fractions, and stem bark extracts, demonstrate its profound pharmacological versatility. Specifically, the plant's fruit has shown promise in addressing metabolic concerns through its hypoglycemic effects. Furthermore, investigations into its chemical constituents suggest a critical role in managing complex conditions such as gastric cancer.
- Synonyms
- Eugenia Alternifolia
- Common names
- Not available
- Family
- Myrtaceae
- Distribution
- Africa
- Plant Parts
- Fruit
Classification
Synonyms
Syzygium alternifolium is a botanical name that refers to a specific species within the myrtle family. In many scientific circles, this plant is also recognized by the synonym Eugenia alternifolia. This dual nomenclature can sometimes cause confusion for researchers and enthusiasts studying its unique characteristics. However, both names ultimately point to the same biological entity regardless of the taxonomic framework used. Understanding these synonym relationships is essential for accurate identification and documentation in botanical studies.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Syzygium alternifolium belongs to the vast kingdom Plantae, representing a diverse branch of the natural world. Within this kingdom, the species is classified under the class Equisetopsida. It further falls into the order Myrtales, which helps define its specific biological characteristics. As a member of the Myrtaceae family, it shares close ties with many other aromatic woody plants. Ultimately, this species is defined by its placement within the distinct genus Syzygium.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Myrtales |
| Family | Myrtaceae |
| Genus | Syzygium |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Syzygium alternifolium is a distinct botanical species primarily located within the tropical regions of Asia. Its natural range is concentrated throughout the Indian Subcontinent, with a particularly strong presence across India. This distribution highlights the plant's adaptation to the warm and humid climates characteristic of these specific geographical areas. Understanding its habitat is essential for researchers studying the biodiversity of the South Asian landscape. Consequently, the species serves as an important component of the local tropical ecosystems it inhabits.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Syzygium alternifolium is a self-supporting plant that exhibits a distinct tree-like growth form. This sturdy structure allows it to stand independently within its natural habitat.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Syzygium alternifolium is an endemic medicinal plant that possesses a diverse range of therapeutic properties. Research indicates that its seed extracts exhibit significant hypoglycemic and antihyperglycemic activities, effectively lowering blood glucose levels in both normal and diabetic subjects. Additionally, the stem bark extract serves as a highly effective medium for synthesizing silver nanoparticles that function as potent antimicrobial agents. The plant's fruits also contain specialized flavonoids that demonstrate promising gastroprotective potential, particularly through their interaction with gastric cancer cell lines. Together, these findings highlight the multifaceted pharmacological importance of this species in developing new natural therapeutics.
Compounds
Conditions
Syzygium alternifolium contains specific flavonoids that serve as potential therapeutic agents against gastric cancer. Researchers isolated three distinct compounds from the fruits of this medicinal plant to examine their antigastric cancer activity on AGS cell lines. Among these, kaempferol-3-O-β-d-glucopyranoside and kaempferol-3-O-α-l-rhamnopyranoside demonstrated significant cytotoxic effects. Molecular docking and dynamic simulations revealed that these flavonoids, particularly compound 2, can effectively inhibit the human growth factor receptor-2 (HER2). These findings suggest that the plant provides a valuable natural source for developing new scaffolds to treat gastric carcinoma.
Preparations
Syzygium alternifolium is prepared as an aqueous extract, an ethanolic extract, and as hexane fractions from its seeds. These different seed preparations are used to evaluate hypoglycemic and antihyperglycemic activities in both normal and diabetic rats. Additionally, the plant is prepared as a stem bark extract to facilitate the green synthesis of silver nanoparticles. This specific stem bark extract contains phenols and proteins that are essential for the capping and stabilization of the resulting nanoparticles. Together, these various extraction methods allow for the study of the plant's medicinal properties ranging from glucose regulation to antimicrobial potential.
Parts used
Syzygium alternifolium serves as a significant source of natural medicinal compounds, particularly through its nutrient-rich fruit. Researchers have successfully isolated specific flavonoids from these fruits to explore their potential in treating gastric cancer. By utilizing silica gel column chromatography and NMR techniques, scientists identified bioactive molecules such as kaempferol derivatives within the plant material. These extracted compounds demonstrated significant cytotoxic effects and the ability to inhibit the human growth factor receptor-2 (HER2). Ultimately, studying the fruit of this plant provides a promising foundation for developing new, natural therapeutic scaffolds for carcinoma treatment.